There have been several targeted therapies under development for the treatment of cancers with KRAS mutations.
One of the most promising targeted therapies for KRAS-mutant cancers is sotorasib (also known as AMG 510). Sotorasib specifically targets the KRAS G12C mutation, which is found in a subset of non-small cell lung cancer (NSCLC), colorectal cancer, and other solid tumors. In May 2021, the United States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of patients with locally advanced or metastatic NSCLC with the KRAS G12C mutation.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf|
Another drug adagrasib (MRTX849), is also being investigated for the treatment of cancers harboring the KRAS G12C mutation. Approved for treatment of non-small cell lung cancer with KRAS G12C mutation.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761198s000lbl.pdf|
There are also several other experimental therapies targeting different KRAS mutations or indirectly affecting the KRAS signaling pathway. These include drugs that target related proteins like SOS1 or SHP2, as well as combination therapies using existing targeted therapies or immunotherapies.
Clinical trials are continuously being conducted to evaluate the safety and efficacy of these targeted therapies for KRAS-mutant cancers. It is crucial to consult with a healthcare professional to determine the most appropriate treatment options based on the specific mutation and cancer type.